Programme

 

PRE-MEETING EVENT

WEDNESDAY, MAY 27, 2020

14.00-17.00 SCNP EDUCATIONAL WORKSHOP

MECHANISM OF ACTION OF RAPID ACTING ANTIDEPRESSANTS

  • Gregers Wegener (Aarhus, Denmark)
  • Halldora Jonsdottir (Reykjavik, Iceland)
  • Bo Söderpalm (Gothenburg, Sweden)

 

THURSDAY, MAY 28, 2020

08.30 – REGISTRATION OPENS (COFFEE)

09.00 - 9.45 SCNP GENERAL ASSEMBLY (MEMBERS ONLY)

9:45 – 9.55 SCNP and KI PRESIDENTS’ WELCOME TO SCNP 61ST ANNUAL MEETING

  • Sophie Erhardt (Stockholm, Sweden)
  • Ole Petter Ottersen (Stockholm, Sweden)

9:55 – 10.15 THEKI PRESIDENTS’ TALK

Role of aquaporin-4 in neurological and psychiatric disorders

  • Ole Petter Ottersen (Stockholm, Sweden)

10.15 - 11.00 SCNP 2020 OPENING LECTURE

Moderator: Sophie Erhardt (Stockholm, Sweden), Gregers Wegener (Aarhus, Denmark)

Translational strategies to develop psychiatric medications: Hopes, disappointments and some lessons learned

  • Markus Heilig (Linköping, Sweden)

11.00 – 13.00 SESSION I

Moderators: Sophie Erhardt (Stockholm, Sweden), Bo Söderpalm (Gothenburg, Sweden)

Rationale for psychedelics in Depression

  • Prof. Ole Andreassen (Oslo, Norway)

Diagnosis and treatment of maladaptive immunological responses presenting with psychiatric phenotypes

  • Janet Cunningham (Uppsala, Sweden)

Treating depressed patients with an IL-6 receptor antagonist

  • Martin Samuelsson (Linköping, Sweden)

Understanding the genetics of psychiatric disorders in the era of GWAS

  • Sarah Bergen (Stockholm, Sweden)

Suicide prevention- how to turn the tide?

  • Merete Nordentoft (Copenhagen, Denmark)

Suicide prevention in Sweden

  • Ullakarin Nyberg (Stockholm, Sweden)

13.00 – 14.00 LUNCH AND POSTER VIEWING

14.00 – 15.30 SCNP YOUNG SCIENTIST SYMPOSIUM

Moderators: Gregers Wegener (Aarhus, Denmark), Olli Kampman (Tampere, Finland)

  • Speakers selected based on competition

15:30 – 16:00 COFFEE BREAK AND POSTER VIEWING

16.00 – 17.30 SESSION II 

Moderators: Ingrid Dieset (Oslo, Norway), Jonas Eberhard (Lund, Sweden)

Inflammation in psychiatric disorders and its relevance for anti-inflammatory treatment

  • Valeria Mondeli (London, UK)

Direct binding of antidepressants to TRKB mediates drug-induced neuroplasticity

  • Plinio Casarotto (Helsinki, Finland)

What happens in the nervous system that makes us perceive something as good or bad, pleasant or painful?

  • Siri Leknes (Oslo, Norway)

17.30 – POSTER VIEWING (REFRESHMENTS)

19:00 – GUIDED TOUR FOLLOWED BY GALA DINNER AT “NATIONALMUSEUM”

 

FRIDAY, MAY 29, 2020

08.30 - 9.10 KEYNOTE LECTURE

Moderators: Mia Eriksson (Gothenburg, Sweden), Nitya Jayaram Lindström (Stockholm, Sweden)

Cannabis — The Good, The Bad and the Ugly in Relation to Psychiatric Disorders

  • Yasmin Hurd, Icahn School of Medicine at Mount Sinai, USA

9.10 – 10.50 SESSION III

Moderators: Ingrid Dieset (Oslo, Norway), Olli Kampman (Tampere, Finland)

Clozapine use in Iceland and Value Based Practice – Is the Risk of Agranulocytosis Overstated?

  • Oddur Ingimarsson (Reykjavík, Iceland)

New insights into the genetic relationship between psychiatric disorders and cognitive function

  • Olav Bjerkehagen Smeland (Oslo, Norway)

Immunopsychiatry and the potential of anti-inflammatory treatment

  • Michael Eriksen Benros (Copenhagen, Denmark)

Treatment of minocycline and schizophrenia

  • Carl Sellgren (Stockholm, Sweden)

Challenges to innovation in an academic health center

  • Martin Schalling (Stockholm, Sweden)

10.50 – 11.20 COFFEE BREAK AND POSTER VIEWING

11.20 – 12.20 UPDATE ON NEW DRUGS

Moderators: Sophie Erhardt (Stockholm, Sweden), Martin Schalling (Stockholm, Sweden)

SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, for the Treatment of Schizophrenia

  • Justine M. Kent, M.D., Head of Global Clinical Research, Psychiatry, at Sunovion

Targeting Brain Kynurenic Acid for Cognitive Improvement

  • Robert Schwarcz, University of Maryland, USA
     

12.20 - 13:20 LUNCH AND POSTER VIEWING

13.20 – 14.20 KEYNOTE LECTURE

Moderators: Ingrid Dieset (Oslo, Norway), Bo Söderpalm (Gothenburg, Sweden)

Treatment Strategies for ADHD and Co-occurring Substance Use/Use Disorders

  • Frances Levin, Columbia University, USA

14.20 – 16.00 SESSION IV

  • Moderators: Markus Heilig (Linköping, Sweden), Halldora Jonsdottir (Reykjavik, Iceland)

The alarming rise in pharmacotherapy in child psychiatry: evidence from patient registry and the needed clinical interventions”

  • Clara Hellner (Stockholm, Sweden)

Role of Cognition in Alcohol Use Disorders

  • Nitya Jayaram Lindström (Stockholm, Sweden)

CDNF in Preclinical Models of Parkinson Disease

  • Merja Voutilainen (Helsinki, Finland)

Gut-brain axis and addictive disorders

  • Elisabet Jerlhag Holm (Gothenburg, Sweden)

Intravenous use of Methylphenidate

  • Guðrún Dóra Bjarnadóttir (Reykjavík, Iceland)

16:00 CONCLUSION OF MEETING

Sophie Erhardt (Stockholm, Sweden), Bo Söderpalm (Gothenburg, Sweden)